This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer. The objective is to evaluate the safety, tolerability and antitumor activity of SSGJ-707 in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
80
SSGJ-707 is a bispecific antibody against human PD-1 and VEGF
chemotherapy
chemotherapy
Chongqing Cancer Hospital
Chongqing, China
RECRUITINGORR
Objective response rate
Time frame: 12 months
Safety and tolerability
Safety and tolerability assessed by incidence and severity of adverse events
Time frame: 12 months
PFS
The efficacy end point
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.